Pursuing Unexplored Targets to halt and reverse fibrotic activity in the clinic
Mediar is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure.
New perspective. Novel targets. Clinical trials.
The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in the organ. This cell is often referred to as the final common pathway in fibrosis and has been a key target of interest. A new class of targets known as fibrotic mediators activate the myofibroblast. These mediators are measurable in plasma, correlate with fibrosis severity, and could be utilized for future precision approaches to treat patients. By neutralizing these proteins with antibodies, we can disable the myofibroblast, slowing fibrosis and enabling tissue regeneration and healing.
Mediar is embarking on Phase 2 clinical studies in fibrosing diseases in 2025 and hopes this is the first step in creating new potential options for patients and their caregivers.
Fearlessly Charting a Different Course Toward Patient Impact
Mediar’s team of industry-leading researchers combines deep fibrosis expertise, antibody engineering knowledge, and translational science proficiency to accelerate clinical proof-of-concept studies. Our clinical team has run Ph-2/Ph-3 studies in several fibrotic diseases, including IPF, liver, and other areas..
Passionately Powered by Science for Patient Impact
